Axonyx (NASDAQ:AXYX)
Historical Stock Chart
From Sep 2019 to Sep 2024
Axonyx Inc. (NASDAQ: AXYX) today announced that Gosse B.
Bruinsma, MD, President and CEO of Axonyx, will be presenting at the
Rodman and Renshaw 3rd Annual Global Healthcare Conference in Monte
Carlo, Monaco on Tuesday, May 16 at 9:25 AM local time (3:25 AM EDT).
Dr. Bruinsma is expected to discuss the Company's clinical development
program, strategic initiatives and market opportunities. Parties
interested in scheduling 1-on-1 meetings with Dr. Bruinsma are invited
to contact Lily Khaykina at LK@rodmanandrenshaw.com.
The presentation will be Web cast live via streaming audio and can
be accessed by visiting the Axonyx Web site at www.axonyx.com. For
those unable to listen to the live Web cast, a replay of the
presentation will be available for 30 days on the Company's Web site.
About Axonyx
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in
the acquisition and development of proprietary pharmaceutical
compounds for the treatment of Central Nervous System disorders. The
Company currently has three compounds in development for Alzheimer's
disease; Phenserine - a potential symptomatic and disease progression
treatment of mild to moderate Alzheimer's disease (AD); Posiphen(TM)-
a potential disease progression treatment for AD now in Phase I; and
Bisnorcymserine (BNC) - a potential symptomatic treatment of severe AD
in the pre-Investigational New Drug (IND) stage.
This press release may contain forward-looking statements or
predictions. These statements represent our judgment to date, and are
subject to risks and uncertainties that could materially affect the
Company, including those risks and uncertainties described in the
documents Axonyx files from time to time with the SEC, specifically
Axonyx's annual report on Form 10-K. Specifically, with respect to our
drug candidates Phenserine, Posiphen(TM) and Bisnorcymserine, Axonyx
cannot assure that: any preclinical studies or clinical trials,
whether ongoing or conducted in the future, will prove successful, and
if successful, that the results can be replicated; safety and efficacy
profiles of any of its drug candidates will be established, or if
established, will remain the same, be better or worse in future
clinical trials, if any; pre-clinical results related to cognition and
the regulation of beta-APP and/or amyloid beta will be substantiated
by ongoing or future clinical trials, if any, or that any of its drug
candidates will be able to improve the signs or symptoms of their
respective clinical indication or slow the progression of Alzheimer's
disease; any of its drug candidates will support an NDA filing, will
be approved by the FDA or its equivalent, or if approved, will prove
competitive in the market; Axonyx will be able to successfully
out-license any of its drug candidates; Axonyx will be able to
successfully in-license any additional compounds; or that Axonyx will
have or obtain the necessary financing to support its drug development
programs. Axonyx cannot assure that it will be successful with regard
to identifying a (sub-) licensing partner for any of its compounds.
Axonyx undertakes no obligation to publicly release the result of any
revisions to such forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.